Silence Therapeutics - A Revolution in Gene Silencing
Silence Therapeutics

On January 5, 2010, Silence Therapeutics completed its merger with Intradigm Corporation.  A new website for the merged company is currently under development.  In the meantime, to learn more about the company that Silence merged with, please visit www.intradigm.com
 

  View a letter from the new Silence Therapeutics CEO, Philip Haworth, JD, Ph.D., discussing the strengths and strategy of the enlarged Silence Therapeutics

 

 


Merger Information

For more information on the merger between Silence Therapeutics and Intradigm, please review the following materials:

Merger press release >>

Article in BioWorld Today >>

Corporate presentation >>

 

 

Document Last Updated ( Friday, 29 January 2010 )
 
Contact Legal Disclaimer Company Info © Silence Therapeutics 2007

In Brief

8 February 2010
Silence Therapeutics Receives Notice of Allowance for RNAi Patent Covering Novel Cancer Target

   Read more...
 

5 February 2010
Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference

   Read more...
 

5 January 2010
Silence and Intradigm complete merger to form a leading company in the field of RNAi

   Read more...
 

4 January 2010
Shareholders pass all resolutions at EGM

   Read more...
 

16 December 2009
Silence Therapeutics to merge with Intradigm Corp to create leading RNAi therapeutics company

   Read more...
 

16 December 2009
Admission Document – Circular to Shareholders in full
download Admission Document

 

14 December 2009
Shareholders pass all resolutions at AGM

   Read more...
 

15 October 2009
Silence Therapeutics’ core patent upheld

   Read more...
 

30 September 2009
Silence announces Interim Results for the six months ended 30 June 2009

   Read more...
 

29 September 2009
Silence announces temporary suspension of shares pending outcome of M&A talks

   Read more...
 

17 September 2009
Silence will release its interim results for the 6 months to 30 June 2009 on 30 September 2009

   Read more...
 

27 August 2009
Silence Therapeutics signs siRNA delivery collaboration with Dainippon Sumitomo Pharma

   Read more...
 

23 June 2009
Silence announces dosing of first patient in Atu027 cancer trial

   Read more...
 

3 June 2009
Silence receives approval to commence Phase I clinical trial with Atu027

   Read more...
 

21 January 2009
Successful oppostion to 2nd EP on Keutzer-Limmer

   Read more...
 

9 January 2009
EPO grants Silence Therapeutics’ Patent

   Read more...